Epirus Biopharmaceuticals Inc. (EPRS) 8.74 $EPRS
How Novartis Drug Approval Makes Biosimilar Makers Ripe for Acquisition
at The Street - Tue Mar 31, 8:13AM CDT
Pfizer, Teva and Actavis are potential consolidators, while Momenta, Coherus and Epirus lead the list of likely targets.
EPRS: 8.74 (-0.25), AMGN: 169.10 (+0.64), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62), CHRS: 24.79 (-0.89)
Raising Price Target On Epirus Biopharma - The Biosimilar Revolution Has Started
Jason Napodano, CFA - at Seeking Alpha - Wed Mar 25, 1:13PM CDT
On March 23, 2015, Epirus Biopharmaceuticals, Inc. (NASDAQ: EPRS ) reported financial results for the fourth quarter and full year ending December 31, 2014. Revenues for the fourth quarter and year were negligible, and the company indicated that in...
EPRS: 8.74 (-0.25)
EPIRUS Biopharmaceuticals to Host Biosimilar Key Opinion Leader Meeting and Webcast on March 30
GlobeNewswire - Wed Mar 25, 6:00AM CDT
EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, today announced that it will host a Key Opinion Leader (KOL) breakfast in New York City focused on offering insights into the evolution of the U.S. regulatory landscape, along with a clinician's perspective on the approval and use of biosimilars. The event and live webcast will take place on Monday, March 30, 2015 from 8:00 to 9:15 a.m. Eastern Time.
EPRS: 8.74 (-0.25)
Biosimilar firms move up
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 12:20PM CDT
EPRS: 8.74 (-0.25), PFNX: 15.12 (+0.42), CHRS: 24.79 (-0.89)
EPIRUS Biopharma Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 6:09AM CDT
EPRS: 8.74 (-0.25)
EPIRUS Biopharmaceuticals beats by $0.19
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 3:42PM CDT
EPRS: 8.74 (-0.25)
EPIRUS Reports Fourth Quarter and Fiscal Year 2014 Financial Results
GlobeNewswire - Mon Mar 23, 3:35PM CDT
EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2014.
EPRS: 8.74 (-0.25)
Nasdaq stocks posting largest percentage decreases
AP - Thu Mar 12, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
CMTL: 30.97 (+0.12), SGMS: 12.48 (+0.25), ANY: 3.33 (-0.16), PTX: 7.44 (-0.05), MRD: 19.19 (+0.06), EPRS: 8.74 (-0.25), AEPI: 53.45 (-1.99), HTHT: 22.54 (+0.06), RESN: 3.77 (-0.06), SALM: 5.43 (+0.03), ACAD: 38.55 (-0.20), LAYN: 5.58 (+0.28), INGN: 36.39 (-0.04), VRA: 14.16 (-0.69), MRVC: 8.51 (+0.15)
LifeSci Capital Initiates Coverage of EPIRUS Biopharmaceuticals
ACCESSWIRE - Wed Mar 11, 8:00AM CDT
Pure-Play Biosimilars Company with Plans to Address the Global Market
EPRS: 8.74 (-0.25)
EPIRUS to Report Fourth Quarter and Fiscal Year 2014 Financial Results on March 24, 2015
GlobeNewswire - Wed Mar 11, 6:00AM CDT
EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, today announced that it will host a conference call and webcast at 10 a.m. Eastern Time on Tuesday, March 24, 2015 to discuss fourth quarter and fiscal year 2014 financial results, and to discuss the Company's progress. The call will be led by Amit Munshi, President and Chief Executive Officer, and Tom Shea, Chief Financial Officer.
EPRS: 8.74 (-0.25)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Feb 20, 8:16AM CST
ANET: 66.27 (+0.40), FUEL: 8.97 (+0.01), EPRS: 8.74 (-0.25), ASTI: 1.07 (+0.04), MEIP: 2.08 (-0.16), OESX: 3.16 (-0.06), GENE: 4.88 (-0.05), CLSN: 2.92 (+0.03), NVO: 56.37 (-0.17), SAAS: 10.39 (+0.05), CRC: 8.79 (-0.18), CLRX: 0.95 (unch), NDLS: 19.73 (+0.31), TRUE: 15.72 (-0.26)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 206.93 (-3.92), ACT: 295.22 (+0.69), MDT: 78.01 (+0.93), XON: 44.53 (+0.36), CTIC: 1.93 (+0.09), PFNX: 15.12 (+0.42), JNJ: 100.43 (+0.13), ANTM: 152.84 (-0.04), NVAX: 8.51 (+0.09), SHPG: 253.58 (+3.70), ABBV: 64.52 (+0.91), TBPH: 18.41 (+0.18), SNY: 51.59 (+0.03), ALQA: 4.88 (+0.33), REGN: 472.63 (+9.41), ONCY: 0.80 (unch), PFE: 34.93 (+0.04), SLXP: 172.96 (+0.15), EPRS: 8.74 (-0.25), AMGN: 169.10 (+0.64), NKTR: 10.90 (+0.16), ZTS: 47.03 (-0.51), GILD: 104.18 (-1.02), ACHN: 10.01 (-0.13), GERN: 4.20 (-0.04)
EPIRUS Biopharmaceuticals (EPRS) Jumps: Stock Up 18.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 7:51AM CST
EPIRUS Biopharmaceuticals (EPRS) was a big mover last session, as the company saw its shares rise nearly 19% on the day.
EPRS: 8.74 (-0.25), AFFX: 12.57 (-0.13)
Biosimilar firms up on Remicade patent rejection
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 11:56AM CST
JNJ: 100.43 (+0.13), PFE: 34.93 (+0.04), AMGN: 169.10 (+0.64), EPRS: 8.74 (-0.25), PFNX: 15.12 (+0.42), HSP: 87.80 (+0.04), NVS: 103.45 (-0.62), CHRS: 24.79 (-0.89)
Pfizer Pays A Pretty Penny For Hospira: Here's What You Need To Know
Brendan O'Boyle - at Seeking Alpha - Tue Feb 10, 8:49AM CST
ABT: 48.35 (+1.23), TARO: 143.40 (-0.31), PFE: 34.93 (+0.04), MYL: 72.40 (-1.67), EPRS: 8.74 (-0.25), TEVA: 63.01 (-1.15), HSP: 87.80 (+0.04)
3 Medical Advancements You May Be Missing Out On
Motley Fool Staff - Motley Fool - Sun Feb 08, 10:02AM CST
Source: 3D Systems. From 3D printing to next-generation cancer killers, there are some medical innovations that could have an incredible impact on patients. Our Motley Fool analysts explain how these next-generation medical advances could reshape...
BIIB: 423.57 (+1.46), ONVO: 5.14 (+0.67), DDD: 30.55 (-0.61), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), EPRS: 8.74 (-0.25), AMGN: 169.10 (+0.64), BMY: 66.60 (-0.21), NVS: 103.45 (-0.62), CELG: 115.54 (+0.72)
How Novartis Drug Approval Makes Biosimilar Makers Ripe for Acquisition
at The Street - Tue Mar 31, 8:13AM CDT
Pfizer, Teva and Actavis are potential consolidators, while Momenta, Coherus and Epirus lead the list of likely targets.
EPRS: 8.74 (-0.25), AMGN: 169.10 (+0.64), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62), CHRS: 24.79 (-0.89)
Raising Price Target On Epirus Biopharma - The Biosimilar Revolution Has Started
Jason Napodano, CFA - at Seeking Alpha - Wed Mar 25, 1:13PM CDT
On March 23, 2015, Epirus Biopharmaceuticals, Inc. (NASDAQ: EPRS ) reported financial results for the fourth quarter and full year ending December 31, 2014. Revenues for the fourth quarter and year were negligible, and the company indicated that in...
EPRS: 8.74 (-0.25)
EPIRUS Biopharmaceuticals to Host Biosimilar Key Opinion Leader Meeting and Webcast on March 30
GlobeNewswire - Wed Mar 25, 6:00AM CDT
EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, today announced that it will host a Key Opinion Leader (KOL) breakfast in New York City focused on offering insights into the evolution of the U.S. regulatory landscape, along with a clinician's perspective on the approval and use of biosimilars. The event and live webcast will take place on Monday, March 30, 2015 from 8:00 to 9:15 a.m. Eastern Time.
EPRS: 8.74 (-0.25)
Biosimilar firms move up
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 12:20PM CDT
EPRS: 8.74 (-0.25), PFNX: 15.12 (+0.42), CHRS: 24.79 (-0.89)
EPIRUS Biopharma Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 6:09AM CDT
EPRS: 8.74 (-0.25)
EPIRUS Biopharmaceuticals beats by $0.19
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 3:42PM CDT
EPRS: 8.74 (-0.25)
EPIRUS Reports Fourth Quarter and Fiscal Year 2014 Financial Results
GlobeNewswire - Mon Mar 23, 3:35PM CDT
EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2014.
EPRS: 8.74 (-0.25)
Nasdaq stocks posting largest percentage decreases
AP - Thu Mar 12, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
CMTL: 30.97 (+0.12), SGMS: 12.48 (+0.25), ANY: 3.33 (-0.16), PTX: 7.44 (-0.05), MRD: 19.19 (+0.06), EPRS: 8.74 (-0.25), AEPI: 53.45 (-1.99), HTHT: 22.54 (+0.06), RESN: 3.77 (-0.06), SALM: 5.43 (+0.03), ACAD: 38.55 (-0.20), LAYN: 5.58 (+0.28), INGN: 36.39 (-0.04), VRA: 14.16 (-0.69), MRVC: 8.51 (+0.15)
LifeSci Capital Initiates Coverage of EPIRUS Biopharmaceuticals
ACCESSWIRE - Wed Mar 11, 8:00AM CDT
Pure-Play Biosimilars Company with Plans to Address the Global Market
EPRS: 8.74 (-0.25)
EPIRUS to Report Fourth Quarter and Fiscal Year 2014 Financial Results on March 24, 2015
GlobeNewswire - Wed Mar 11, 6:00AM CDT
EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, today announced that it will host a conference call and webcast at 10 a.m. Eastern Time on Tuesday, March 24, 2015 to discuss fourth quarter and fiscal year 2014 financial results, and to discuss the Company's progress. The call will be led by Amit Munshi, President and Chief Executive Officer, and Tom Shea, Chief Financial Officer.
EPRS: 8.74 (-0.25)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Feb 20, 8:16AM CST
ANET: 66.27 (+0.40), FUEL: 8.97 (+0.01), EPRS: 8.74 (-0.25), ASTI: 1.07 (+0.04), MEIP: 2.08 (-0.16), OESX: 3.16 (-0.06), GENE: 4.88 (-0.05), CLSN: 2.92 (+0.03), NVO: 56.37 (-0.17), SAAS: 10.39 (+0.05), CRC: 8.79 (-0.18), CLRX: 0.95 (unch), NDLS: 19.73 (+0.31), TRUE: 15.72 (-0.26)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 206.93 (-3.92), ACT: 295.22 (+0.69), MDT: 78.01 (+0.93), XON: 44.53 (+0.36), CTIC: 1.93 (+0.09), PFNX: 15.12 (+0.42), JNJ: 100.43 (+0.13), ANTM: 152.84 (-0.04), NVAX: 8.51 (+0.09), SHPG: 253.58 (+3.70), ABBV: 64.52 (+0.91), TBPH: 18.41 (+0.18), SNY: 51.59 (+0.03), ALQA: 4.88 (+0.33), REGN: 472.63 (+9.41), ONCY: 0.80 (unch), PFE: 34.93 (+0.04), SLXP: 172.96 (+0.15), EPRS: 8.74 (-0.25), AMGN: 169.10 (+0.64), NKTR: 10.90 (+0.16), ZTS: 47.03 (-0.51), GILD: 104.18 (-1.02), ACHN: 10.01 (-0.13), GERN: 4.20 (-0.04)
EPIRUS Biopharmaceuticals (EPRS) Jumps: Stock Up 18.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 7:51AM CST
EPIRUS Biopharmaceuticals (EPRS) was a big mover last session, as the company saw its shares rise nearly 19% on the day.
EPRS: 8.74 (-0.25), AFFX: 12.57 (-0.13)
Biosimilar firms up on Remicade patent rejection
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 11:56AM CST
JNJ: 100.43 (+0.13), PFE: 34.93 (+0.04), AMGN: 169.10 (+0.64), EPRS: 8.74 (-0.25), PFNX: 15.12 (+0.42), HSP: 87.80 (+0.04), NVS: 103.45 (-0.62), CHRS: 24.79 (-0.89)
Pfizer Pays A Pretty Penny For Hospira: Here's What You Need To Know
Brendan O'Boyle - at Seeking Alpha - Tue Feb 10, 8:49AM CST
ABT: 48.35 (+1.23), TARO: 143.40 (-0.31), PFE: 34.93 (+0.04), MYL: 72.40 (-1.67), EPRS: 8.74 (-0.25), TEVA: 63.01 (-1.15), HSP: 87.80 (+0.04)
3 Medical Advancements You May Be Missing Out On
Motley Fool Staff - Motley Fool - Sun Feb 08, 10:02AM CST
Source: 3D Systems. From 3D printing to next-generation cancer killers, there are some medical innovations that could have an incredible impact on patients. Our Motley Fool analysts explain how these next-generation medical advances could reshape...
BIIB: 423.57 (+1.46), ONVO: 5.14 (+0.67), DDD: 30.55 (-0.61), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), EPRS: 8.74 (-0.25), AMGN: 169.10 (+0.64), BMY: 66.60 (-0.21), NVS: 103.45 (-0.62), CELG: 115.54 (+0.72)
